Insulin resistance and endothelial dysfunction: A mutual relationship in cardiometabolic risk

Current Pharmaceutical Design

Volumn 19, Issue 13, 2013, Pages 2420-2431

  Del Turco, Serena ^a   Gaggini, Melania ^a,b   Daniele, Giuseppe ^b,c   Basta, Giuseppina ^a   Folli, Franco ^c   Sicari, Rosa ^a   Gastaldelli, Amalia ^a,c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cardiometabolic risk; Endothelial dysfunction; Insulin resistance; Insulin signaling pathways

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CD36 ANTIGEN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; FENOFIBRATE; GLUCAGON LIKE PEPTIDE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIOGLITAZONE; RESISTIN; SOMATOMEDIN RECEPTOR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA;

BLOOD VESSEL REACTIVITY; CARDIOMETABOLIC RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EXERCISE; GENETIC PREDISPOSITION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOTOXICITY; LOW CALORY DIET; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; METABOLIC DISEASES; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84877822919     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319130010     Document Type: Review

References (160)

1. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444(7121): 881-7.
3. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA: J Am Med Association 2012; 307(5): 483-90.
4. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA: J Am Med Association 2012; 307(5): 491-7.
5. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93(2): 136-41.
6. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): 1245-50.
7. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.
8. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119(10): 812-9.
9. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am College Cardiol 2007; 49(4): 403-14.
10. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9): 2289-304.
11. Leiter LA, Fitchett DH, Gilbert RE, et al. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol 2011; 27(2): 124-31.
12. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20(11 Suppl 2): II-3-10.
13. De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997; 39(4): 325-42.
14. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101(16): 1899-906.
15. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97(11): 2601-10.
16. Cleland SJ, Petrie JR, Small M, et al. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000; 35(1 Pt 2): 507-11.
17. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98(4): 894-8.
18. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biological Chem 2001; 276(32): 30392-8.
19. Vincent MA, Dawson D, Clark AD, et al. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 2002; 51(1): 42-8.
20. Baron AD, Brechtel-Hook G, Johnson A, et al. Effect of perfusion rate on the time course of insulin-mediated skeletal muscle glucose uptake. Am J Physiol 1996; 271(6 Pt 1): E1067-72.
21. Vincent MA, Barrett EJ, Lindner JR, et al. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003; 285(1): E123-9.
22. Zhang L, Vincent MA, Richards SM, et al. Insulin sensitivity of muscle capillary recruitment in vivo. Diabetes 2004; 53(2): 447-53.
23. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro-and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 2004; 286(6): E896-901.
24. Cheatham B, Vlahos CJ, Cheatham L, et al. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994; 14(7): 4902-11.
25. Le Marchand-Brustel Y, Gautier N, Cormont M, Van Obberghen E. Wortmannin inhibits the action of insulin but not that of okadaic acid in skeletal muscle: comparison with fat cells. Endocrinology 1995; 136(8): 3564-70.
26. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997; 46(3): 524-7.
27. Kim YB, Nikoulina SE, Ciaraldi TP, et al. Normal insulindependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 1999; 104(6): 733-41.
28. King GL, Buzney SM, Kahn CR, et al. Differential responsiveness to insulin of endothelial and support cells from micro-and macrovessels. J Clin Invest 1983; 71(4): 974-9.
29. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101(13): 1539-45.
30. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998; 182(1-2): 3-11.
31. Sale EM, Sale GJ. Protein kinase B: signalling roles and therapeutic targeting. Cell Mol Life Sci 2008; 65(1): 113-27.
32. Farese RV, Sajan MP, Standaert ML. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp Biol Med (Maywood) 2005; 230(9): 593-605.
33. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101(6): 676-81.
34. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83(5): 1774-7.
35. Sudano I, Spieker LE, Hermann F, et al. Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol 2006; 47 Suppl 2: S136-50; discussion S72-6.
36. Potenza MA, Marasciulo FL, Chieppa DM, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289(2): H813-22.
37. Kelly LK, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol 2004; 286(5): L984-91.
38. Cardillo C, Campia U, Kilcoyne CM, et al. Improved endotheliumdependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002; 105(4): 452-6.
39. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-904.
40. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. The Journal of biological chemistry 2002; 277(3): 1794-9.
41. Mukai Y, Wang CY, Rikitake Y, Liao JK. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2007; 292(4): H1937-42.
42. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100(5): 1230-9.
43. Potdar S, Kavdia M. NO/peroxynitrite dynamics of high glucoseexposed HUVECs: chemiluminescent measurement and computational model. Microvascular research 2009; 78(2): 191-8.
44. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22(6): 423-36.
45. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002; 51 Suppl 1: S212-20.
46. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004; 47(1): 31-9.
47. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105(3): 311-20.
48. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105(5): 576-82.
49. Combettes-Souverain M, Issad T. Molecular basis of insulin action. Diabetes Metab 1998; 24(6): 477-89.
50. Ruiz-Torres A, Lozano R, Melon J, Carraro R. On how insulin may influence ageing and become atherogenic throughout the insulinlike growth factor-1 receptor pathway: in vitro studies with human vascular smooth muscle cells. Gerontology 2005; 51(4): 225-30.
51. Madonna R, Pandolfi A, Massaro M, et al. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004; 47(3): 532-6.
52. Madonna R, Massaro M, Pandolfi A, et al. The prominent role of p38 mitogen-activated protein kinase in insulin-mediated enhancement of VCAM-1 expression in endothelial cells. Int J Immunopathol Pharmacol 2007; 20(3): 539-55.
53. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. Journal of the American College of Cardiology 1996; 27(3): 528-35.
54. Sarafidis PA, Bakris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007; 92(2): 379-85.
55. Sironi AM, Sicari R, Folli F, Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. Current pharmaceutical design 2011; 17(28): 3074-80.
56. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53(7): 1270-87.
57. Zechner R, Strauss JG, Haemmerle G, et al. Lipolysis: pathway under construction. Current opinion in lipidology 2005; 16(3): 333-40.
58. Zimmermann R, Strauss JG, Haemmerle G, et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004; 306(5700): 1383-6.
59. Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends in cardiovascular medicine 2004; 14(5): 202-6.
60. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005; 54(6): 1640-8.
61. Wang XL, Zhang L, Youker K, et al. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 2006; 55(8): 2301-10.
62. Chinen I, Shimabukuro M, Yamakawa K, et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148(1): 160-5.
63. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49(11): 1939-45.
64. Watanabe S, Tagawa T, Yamakawa K, et al. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2005; 25(11): 2376-80.
65. Egan BM, Hennes MM, Stepniakowski KT, et al. Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 1996; 27(3 Pt 2): 723-8.
66. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002; 51(7): 2005-11.
67. Liu GX, Hanley PJ, Ray J, Daut J. Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart. Circulation research 2001; 88(9): 918-24.
68. Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMPdependent protein kinase. Arterioscler Thromb Vasc Biol 2005; 25(8): 1551-7.
69. Goldberg IJ, Dansky HM. Diabetic vascular disease: an experimental objective. Arterioscler Thromb Vasc Biol 2006; 26(8): 1693-701.
70. Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am 2008; 37(3): 685-711, ix-x.
71. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108(9): 1341-8.
72. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93(4): 1143-52.
73. Miele C, Riboulet A, Maitan MA, et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biological Chem 2003; 278(48): 47376-87.
74. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105(7): 816-22.
75. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am College Cardiol 2005; 46(11): 1978-85.
76. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am College of Cardiol 2008; 52(15): 1201-10.
77. Hennige AM, Stefan N, Kapp K, et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. Faseb J 2006; 20(8): 1206-8.
78. van der Vleuten GM, Veerkamp MJ, van Tits LJ, et al. Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD. Atherosclerosis 2005; 183(2): 355-60.
79. Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biological Chem 2003; 278(45): 45021-6.
80. Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circulatory Physiol 2005; 288(5): H2031-41.
81. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA: J Am Medical Association 2004; 291(14): 1730-7.
82. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30(5): 234-9.
83. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferatoractivated receptor-gamma-mediated effects in the vasculature. Circulation Res 2008; 102(3): 283-94.
84. Tuttolomondo A, La Placa S, Di Raimondo D, et al. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular comorbidity. Cardiovascular diabetology.9: 50.
85. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nature clinical practice 2009; 6(1): 27-35.
86. Del Turco S, Navarra T, Gastaldelli A, Basta G. Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvascular Res 2011; 82(1): 73-6.
87. Kobashi C, Urakaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circulation Res 2005; 97(12): 1245-52.
88. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102(11): 1296-301.
89. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46(11): 1543-9.
90. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89(2): 765-9.
91. Chang J, Li Y, Huang Y, et al. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes.59(11): 2949-59.
92. Fadini GP, Avogaro A, Ferraccioli G, Agostini C. Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J.35(2): 418-25.
93. Makino H, Okada S, Nagumo A, et al. Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res Clin Pract 2008; 81(3): 327-30.
94. Werner C, Kamani CH, Gensch C, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007; 56(10): 2609-15.
95. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011; 22(7): 259-65.
96. Bo S, Gambino R, Pagani A, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J obesity (2005) 2005; 29(11): 1315-20.
97. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clinical Immunol (Orlando, Fla 2009; 133(2): 157-70.
98. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 2005; 109(3): 243-56.
99. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophy Res Communications 2009; 383(4): 503-8.
100. Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection? Curr Opinion Pharmacol 2009; 9(2): 202-7.
101. Eringa EC, Stehouwer CD, Walburg K, et al. Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor-alpha dependence on c-Jun Nterminal kinase. Arterioscler Thromb Vasc Biol 2006; 26(2): 274-80.
102. Rask-Madsen C, Dominguez H, Ihlemann N, et al. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 2003; 108(15): 1815-21.
103. Martens FM, Rabelink TJ, op 't Roodt J, et al. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 2006; 27(13): 1605-9.
104. Nguyen MT, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biological Chem 2005; 280(42): 35361-71.
105. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biological Chem 2004; 279(17): 17070-8.
106. Plomgaard P, Bouzakri K, Krogh-Madsen R, et al. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005; 54(10): 2939-45.
107. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents 2004; 2(3): 197-208.
108. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of Creactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107(5): 671-4.
109. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24(3): 278-301.
110. Collot-Teixeira S, Martin J, McDermott-Roe C, et al. CD36 and macrophages in atherosclerosis. Cardiovascular Res 2007; 75(3): 468-77.
111. Handberg A, Hojlund K, Gastaldelli A, et al. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Int Med 2012; 271(3): 294-304.
112. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab 2011; 301(2): E252-63.
113. Sundell J, Nuutila P, Laine H, et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes 2002; 51(4): 1125-30.
114. Yki-Jarvinen H, Westerbacka J. Insulin resistance, arterial stiffness and wave reflection. Adv Cardiol 2007; 44: 252-60.
115. Wiggam MI, Hunter SJ, Ennis CN, et al. Insulin action and skeletal muscle blood flow in patients with Type 1 diabetes and microalbuminuria. Diabetes Res Clin Pract 2001; 53(2): 73-83.
116. Lautamaki R, Airaksinen KE, Seppanen M, et al. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes 2006; 55(2): 511-6.
117. Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 1991; 73(3): 637-43.
118. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103(10): 1410-5.
119. Kemppainen J, Tsuchida H, Stolen K, et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003; 550(Pt 1): 305-15.
120. Mishra M, Kumar H, Bajpai S, et al. Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. Diabetes Res Clin Pract 2011; 94(2): 255-61.
121. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101(15): 1780-4.
122. Baron AD, Steinberg HO, Chaker H, et al. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96(2): 786-92.
123. Mather K, Verma S. Function determines structure in the vasculature: lessons from insulin resistance. Am J Physiol Regul Integr Comp Physiol 2005; 289(2): R305-R6.
124. Clerk LH, Vincent MA, Jahn LA, et al. Obesity blunts insulinmediated microvascular recruitment in human forearm muscle. Diabetes 2006; 55(5): 1436-42.
125. Gudbjornsdottir S, Sjostrand M, Strindberg L, Lonnroth P. Decreased muscle capillary permeability surface area in type 2 diabetic subjects. J Clin Endocrinol Metab 2005; 90(2): 1078-82.
126. Scognamiglio R, Negut C, De Kreutzenberg SV, et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112(2): 179-84.
127. Okon EB, Chung AW, Rauniyar P, et al. Compromised arterial function in human type 2 diabetic patients. Diabetes 2005; 54(8): 2415-23.
128. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-50.
129. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.
130. Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007; 4(3): e76.
131. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterraneanstyle diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA: J Am Med Association 2004; 292(12): 1440-6.
132. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26(7): 2119-25.
133. De Filippis E, Cusi K, Ocampo G, et al. Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91(12): 4903-10.
134. Sasaki S, Higashi Y, Nakagawa K, et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15(4 Pt 1): 302-9.
135. Vincent MA, Clerk LH, Lindner JR, et al. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. Am J Physiol Endocrinol Metab 2006; 290(6): E1191-7.
136. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am College Cardiol 2001; 37(5): 1344-50.
137. Matsumoto T, Noguchi E, Ishida K, et al. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 2008; 295(3): H1165-H76.
138. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854-65.
139. Fujishima S, Ohya Y, Nakamura Y, et al. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 1998; 11(9): 1134-7.
140. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50(4): 1087-93.
141. Gastaldelli A, Casolaro A, Ciociaro D, et al. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2009; 297(1): E225-30.
142. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-gamma activators. Circulation 2000; 101(3): 235-8.
143. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21(12): 1891-5.
144. Rizza S, Cardellini M, Porzio O, et al. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 2011; 215(1): 180-3.
145. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59(4): 1030-7.
146. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287(6): E1209-15.
147. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201(1): 59-66.
148. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25(9): 1129-31.
149. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13(4): 302-12.
150. Hirata K, Kume S, Araki S, et al. Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Communications 2009; 380(1): 44-9.
151. Panunti B, Kunhiraman B, Fonseca V. The impact of antidiabetic therapies on cardiovascular disease. Curr Atheroscler Rep 2005; 7(1): 50-7.
152. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286(15): 1882-5.
153. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112(1): 48-53.
154. Investigators HOPES. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355(9200): 253-9.
155. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted crosstalk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006; 22(2): 98-107.
156. Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100(9): 2158-69.
157. Calegari VC, Alves M, Picardi PK, et al. Suppressor of cytokine signaling-3 Provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 2005; 146(2): 579-88.
158. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109(17): 2054-7.
159. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110(24): 3687-92.
160. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42(1): 76-81.